KPC Presence in Pseudomonas aeruginosa Has Minimal Impact on the In Vivo Efficacy of Carbapenem Therapy | Zendy

Mao Hagihara | Zendy; Jared L. Crandon | Zendy; Carl Urban | Zendy; David P. Nicolau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KPC Presence in Pseudomonas aeruginosa Has Minimal Impact on the In Vivo Efficacy of Carbapenem Therapy

Author(s) -

Mao Hagihara,

Jared L. Crandon,

Carl Urban,

David P. Nicolau

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01748-12

Subject(s) - pseudomonas aeruginosa , klebsiella pneumoniae , in vivo , potency , microbiology and biotechnology , carbapenem , biology , in vitro , antibiotics , bacteria , escherichia coli , gene , genetics , biochemistry

While reports ofKlebsiella pneumoniae carbapenemase (KPC) production amongPseudomonas aeruginosa strains have emerged from a number of countries worldwide, outcome data are lacking. This is the first report evaluating how KPC production inP. aeruginosa impacts the efficacy of carbapenems by using the murine thigh infection model. Our findings suggest that the impact of KPC-2in vivo is less pronounced than would be anticipated based on thein vitro potency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research